CLINUVEL PHARMACEUTICALS WKN: A0JEGY ISIN: AU000000CUV3 Forum: Aktien Thema: Hauptdiskussion

Hat Disc Medicine die Zusage?

Naja die Konkurrenz schläft nicht, abbvie hat ein Konkurrenzprodukt vorgestellt, jetzt muss clinuvel halt liefern und wenn endlich geliefert wird kommt der Kurs auch wieder. Wird ein spannendes Jahr

Was ist denn los mit der Aktie? Warum immer dieses Trauerspiel?

Kommen endlich wieder zurück. Mal sehen ob es diesmal klappt

https://www.tipranks.com/news/company-announcements/clinuvel-reports-new-positive-vitiligo-data-for-scenesse-in-darker-skinned-patients

Ab 11:40 min https://www.youtube.com/watch?v=ysv1s6JuDNI

https://www.noz.de/lebenswelten/gesundheit-fitness/artikel/wenn-sonne-die-haut-verbrennt-leben-mit-unheilbarer-krankheit-49119622

https://www.clinuvel.com/2025/12/clinuvel-progresses-level-ii-adr-upgrade-nasdaq-uplist-20251219/

CLINUVEL today announced that it has filed a draft registration statement with the U.S. Securities and Exchange Commission (SEC), a key step to uplisting its American Depositary Receipt (ADR) program on the Nasdaq Stock Market.

Jetzt in wichtigem Widerstandsbereich

https://www-minussinus-de.translate.goog/2025/11/03/clinuvel-der-farbe-beim-trocknen-zusehen-2/?_x_tr_sl=de&_x_tr_tl=en&_x_tr_hl=de&_x_tr_pto=wapp

Hier mal die Antwort von Clinuvel auf meine Email: On the issues you raise: • The potential of competition is not new but heightened recently by announcements of Disc Medicine. External analysts see multiple therapies able to treat EPP viably and CLINUVEL management have also answered questions on this issue in webinars. • The lack of relationship between CLINUVEL’s performance and its share price was covered by the MD in the 2024 AGM (attached for your ease of reference). CLINUVEL is not alone in experiencing a declining share price in an unsettled and negative overall biotech market. The best way we can help shareholders is to build the business for the future. • The Company has explained its approach to capital management, and I suggest you review the MD’s address to the 2025 AGM (attached) which explains why cash reserves are allocated to expansion initiatives over share buy-backs. • We are intending to uplift Level I ADRs to Level II ADS on the Nasdaq; this relates to circa 7% of issued capital and is not considered a ‘great’ risk. The Company has demonstrated that it has been able to manage a myriad of risks – clinical studies, regulatory approvals, product development, and commercial operations, to name a few. We have built a highly profitable business with a very positive future. We have explained our strategy and initiatives to diversify the business for a long-term sustainable future. The Chair and MD addresses to the 2025 AGM (attached) convey what we are doing and how we are progressing. The time is for deliberate and considered execution of a well-developed strategy and that is what we are doing.

https://youtu.be/kq_RPgdC3x4?si=qZRq3TMexKXFCsNj

https://youtu.be/_0gnsN37hlE?si=tAW-L0M7pFYng4oI

Clinuvel Update https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=XNPAGHCQYS

https://www.top-magazin-frankfurt.de/health/clinuvel-photocosmetics-braeune-ohne-sonne/